Sustainability in the Pharmaceutical Industry
The pharmaceutical industry significantly impacts the environment due to the generation of hazardous waste, the use of energy and water, and the emission of greenhouse gases. [...]
World AIDS Day: HIV Statistics and the Role of Drug Delivery Innovation
Every December 1, World AIDS Day is commemorated worldwide, dedicated to raising awareness about the global AIDS epidemic caused by the spread of HIV. [...]
Clinical Studies for Generic Transdermal Patches: Bioequivalence, Adhesion, and Skin Safety Requirements
The clinical requirements for generic transdermal patch approval are substantially more demanding than those for conventional oral dosage forms. A generic tablet typically needs to demonstrate pharmacokinetic bioequivalence in a single crossover study. A generic patch requires bioequivalence under single and multiple dose schemes, statistical non-inferiority in adhesion performance, and [...]
World Mental Health Day
October 10 marks World Mental Health Day. This is an opportunity to talk about mental health in general, how we should take care of it, and how important it is to get help if you're struggling. [...]
New methylphenidate transdermal patch for Attention Deficit of Hyperactivity Disorder (ADHD)
In October, we join to the awareness campaigns on ADHD by sharing this article that briefly describes the characteristics of transdermal system containing methylphenidate that has been recently developed by Amarin Technologies for the treatment of this condition. [...]
Novartis’ Ballet
Exelon® should be featured in pharmaceutical marketing courses as one of the best success stories when it comes to life cycle management. In the following article, we tell the reasons [...]
Big data and pharma
The use of new tools to explore Big Data sets has accelerated their use in the field of health. [...]
Pharmaceutical CDMO Out-Licensing Strategy: How Amarin Technologies Built Global Reach from Argentina
Amarin Technologies operates as a pharmaceutical CDMO with an out-licensing strategy in one of the more challenging operating environments in the world, Argentina. For potential partners evaluating a CDMO for transdermal development, licensing, or commercial supply agreements, the Argentine context is either a concern or, on closer examination, evidence of [...]
API characteristics for Transdermal Drug Delivery Systems
In order for an IFA to be administered through the skin, it must meet certain characteristics. [...]